Stutvoet et al. found that the activity of MAPK pathway plays a key role in the expression of PD-L1 in lung adenocarcinoma induced by EGF and IFN γ, However, MAPK pathway does not change the targeted genes, so MAPK may be a target to improve the efficacy of immunotherapy [25]. Here, EGF is linked to lung adenocarcinoma.